Molbio Diagnostics
Price Band
₹768 - ₹807
Lot Size
18 Shares
Issue Size
₹939.70 Cr
Fresh Issue
₹200.00 Cr
OFS
₹739.70 Cr
Registrar
AI Sentiment Score
Listing Price
₹980.00
vs Issue: ₹807 (+21.44%)
📅 IPO Timeline
✓
Open
Aug 10, 2026
✓
Close
Aug 12, 2026
✓
Allotment
Aug 13, 2026
✓
Refund
Aug 14, 2026
✓
Demat
Aug 14, 2026
✓
Listing
Aug 17, 2026
📈 Grey Market Premium (GMP) Trendline
Daily consensus GMP movement (₹) recorded across market sources
✨ AI Analysis & Prediction
🔒 Final Reconciled Estimate
Locked post-listing with actual debut performance
Molbio Diagnostics displays an established operational footprint with expanding revenue streams (31.4% CAGR) and a defensible value proposition.
💪 Strengths
- Demonstrated operational revenue trajectory with resilient top-line growth (31.4% CAGR).
- Established customer relationships and market position across target industry sectors.
- Sound operational capital returns with Return on Capital Employed (ROCE) at 18.5%.
⚠️ Weaknesses
- Exposure to input cost fluctuations and broader macroeconomic supply chain cycles.
- Working capital requirements to support continuous capacity expansion.
- Competitive landscape from both established incumbents and specialized regional players.
🚀 Opportunities
- Industry tailwinds from rising domestic capex and infrastructure spending.
- Operating leverage potential allowing margin expansion as manufacturing utilization rises.
- Geographic diversification and entry into higher-margin specialized product lines.
🛡️ Threats
- Sectoral regulatory shifts and evolving statutory compliance requirements.
- Aggressive pricing actions by domestic competitors impacting gross margins.
- Broader market equity volatility and liquidity fluctuations.
🎯 Objectives of the IPO
| Requirement / Purpose | Amount (₹ Cr) |
|---|---|
| Funding capital expenditure towards the setting up of infrastructure for our research and development facility, Center of Excellence and connected office space. | ₹118.08 |
| Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit, and | ₹79.04 |
| General corporate purposes | ₹742.58 |
📊 Financial Overview & Growth Trajectory
Multi-year operational scale & net profitability trajectory
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue (₹ Cr) | Rs 837.00 Cr | Rs 1,020.00 Cr | Rs 1,446.00 Cr |
| Net Profit / PAT (₹ Cr) | Rs 84.00 Cr | Rs 139.00 Cr | Rs 164.00 Cr |
| EBITDA / Op. Profit (₹ Cr) | Rs 234.00 Cr | Rs 260.00 Cr | Rs 320.00 Cr |
| Borrowings (₹ Cr) | Rs 184.00 Cr | Rs 147.00 Cr | Rs 450.00 Cr |
| Total Assets (₹ Cr) | Rs 1,218.00 Cr | Rs 1,461.00 Cr | Rs 2,115.00 Cr |
| ROE % | 0.00% | 0.00% | 0.00% |
| ROCE % | 18.50% | 18.50% | 18.50% |
| Debt / Equity | 0.00 | 0.00 | 0.00 |
Company P/E
69.3x
Industry P/E
79.7x
Debt/Equity
0.38
⚖️ Valuation Benchmark Range
🟢 Attractively Priced vs Industry Peers
Industry 79.7x
IPO 69.3x
0x (Deep Value)
108x (High Multiple)
📋 Live Subscription Status
QIB
186.39x
NII
50.82x
Retail
12.96x
Total
70.26x
🎯 Retail Allotment Probability
7.7% Odds
1 in 13.0 chance (~7.7% probability per PAN)
SEBI Rule: Under SEBI lottery allotment rules, applying for multiple lots under Retail does NOT increase your lottery odds. All valid retail applicants have identical 1-lot odds per PAN.
Updated: Sep 12, 2026 2:29 PM
💼 Issue Structure & Reservation Quota
Capital Structure
₹939.7 Cr
Issue Size
Fresh (21.3%)
OFS (78.7%)
Reservation Quota
100%
Allocation
QIB (50%)
NII (15%)
Retail (35%)
QIB
50.00%
Retail
35.00%
NII
15.00%
📈 Shareholding & Anchor Lock-In
🔗 Important Links & Lead Managers
- Check Allotment StatusCheck Now →
- Registrar WebsiteVisit →
- Download DRHP ProspectusDownload PDF 📥
- Download RHP ProspectusDownload PDF 📥
Lead Managers / Merchant Bankers
This issue is managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd.
Disclaimer: The information provided on this page is for educational and informational purposes only and does not constitute financial advice. IPO investments are subject to market risks. AI-generated analysis is based on publicly available data and may not be accurate. Grey Market Premium (GMP) is unofficial and highly speculative. Always consult a qualified financial advisor and read the DRHP/RHP carefully before making investment decisions.